Yamanashi Y, Ohmichi M, Ohmichi Y, Ikemoto T, Arai Y, Maruyama Y
J Inflamm Res. 2021; 14:3247-3259.
PMID: 34290513
PMC: 8289442.
DOI: 10.2147/JIR.S318540.
Duong N, Curley K, Brown A, Campanelli A, Do M, Levy D
Int J Nanomedicine. 2019; 14:3413-3425.
PMID: 31190800
PMC: 6514129.
DOI: 10.2147/IJN.S196975.
Haleagrahara N, Hodgson K, Miranda-Hernandez S, Hughes S, Kulur A, Ketheesan N
Inflammopharmacology. 2018; 26(5):1219-1232.
PMID: 29616452
DOI: 10.1007/s10787-018-0464-2.
Abdel-Azeem A, Zaki S, Khalil W, Makhlouf N, Farghaly L
Front Microbiol. 2016; 7:1477.
PMID: 27703452
PMC: 5029229.
DOI: 10.3389/fmicb.2016.01477.
Bauerova K, Ponist S, Mihalova D, Drafi F, Kuncirova V
Interdiscip Toxicol. 2011; 4(1):33-9.
PMID: 21577282
PMC: 3090052.
DOI: 10.2478/v10102-011-0007-9.
Intravenous daclizumab for recalcitrant ocular inflammatory disease.
Bhat P, Castaneda-Cervantes R, Doctor P, Foster C
Graefes Arch Clin Exp Ophthalmol. 2009; 247(5):687-92.
PMID: 19198869
DOI: 10.1007/s00417-009-1043-4.
Indian herbal medicines: possible potent therapeutic agents for rheumatoid arthritis.
Rathore B, Mahdi A, Paul B, Narayan Saxena P, Das S
J Clin Biochem Nutr. 2008; 41(1):12-7.
PMID: 18392103
PMC: 2274991.
DOI: 10.3164/jcbn.2007002.
Biological response modifier therapy for refractory childhood uveitis.
Gallagher M, Quinones K, Cervantes-Castaneda R, Yilmaz T, Foster C
Br J Ophthalmol. 2007; 91(10):1341-4.
PMID: 17556427
PMC: 2000999.
DOI: 10.1136/bjo.2007.124081.
Management of sight-threatening uveitis: new therapeutic options.
Becker M, Smith J, Max R, Fiehn C
Drugs. 2005; 65(4):497-519.
PMID: 15733012
DOI: 10.2165/00003495-200565040-00005.
The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis.
Firestein G
J Clin Invest. 2004; 114(4):471-4.
PMID: 15314683
PMC: 503778.
DOI: 10.1172/JCI22651.
Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation.
Arrington J, Chapkin R, Switzer K, Morris J, McMurray D
Clin Exp Immunol. 2001; 125(3):499-507.
PMID: 11531960
PMC: 1906146.
DOI: 10.1046/j.1365-2249.2001.01627.x.
TCR peptide therapy in human autoimmune diseases.
Vandenbark A, Morgan E, Bartholomew R, Bourdette D, Whitham R, CARLO D
Neurochem Res. 2001; 26(6):713-30.
PMID: 11519731
DOI: 10.1023/a:1010951706830.
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.
Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T
Arthritis Res. 2001; 3(4):247-52.
PMID: 11438043
PMC: 34114.
DOI: 10.1186/ar309.
HLA-DRB1 gene transcripts in rheumatoid arthritis.
Combe B, Vincent R, Clot J, Pinet V, Eliaou J
Clin Exp Immunol. 2001; 124(1):142-9.
PMID: 11359453
PMC: 1906025.
DOI: 10.1046/j.1365-2249.2001.01498.x.
Gene therapy for rheumatoid arthritis.
Gouze E, Ghivizzani S, Robbins P, Evans C
Curr Rheumatol Rep. 2001; 3(1):79-85.
PMID: 11177774
DOI: 10.1007/s11926-001-0054-x.
Use of biologics in the treatment of childhood rheumatic diseases.
Arkachaisri T, Lehman T
Curr Rheumatol Rep. 2000; 2(4):330-6.
PMID: 11123079
DOI: 10.1007/s11926-000-0071-1.
A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?.
Benoist C, Mathis D
Arthritis Res. 2000; 2(2):90-4.
PMID: 11094418
PMC: 129991.
DOI: 10.1186/ar73.
Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.
Williams R, Feldmann M, Maini R
Ann Rheum Dis. 2000; 59 Suppl 1:i75-80.
PMID: 11053094
PMC: 1766633.
DOI: 10.1136/ard.59.suppl_1.i75.
C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.
Youssef S, Maor G, Wildbaum G, Grabie N, Karin N
J Clin Invest. 2000; 106(3):361-71.
PMID: 10930439
PMC: 314324.
DOI: 10.1172/JCI9109.
FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.
Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S
Br J Pharmacol. 2000; 130(7):1655-63.
PMID: 10928971
PMC: 1572228.
DOI: 10.1038/sj.bjp.0703472.
